Literature DB >> 16829629

Recombinant human VEGF treatment transiently increases lung edema but enhances lung structure after neonatal hyperoxia.

Anette M Kunig1, Vivek Balasubramaniam, Neil E Markham, Gregory Seedorf, Jason Gien, Steven H Abman.   

Abstract

Recent studies suggest that VEGF may worsen pulmonary edema during acute lung injury (ALI), but, paradoxically, impaired VEGF signaling contributes to decreased lung growth during recovery from ALI due to neonatal hyperoxia. To examine the diverse roles of VEGF in the pathogenesis of and recovery from hyperoxia-induced ALI, we hypothesized that exogenous recombinant human VEGF (rhVEGF) treatment during early neonatal hyperoxic lung injury may increase pulmonary edema but would improve late lung structure during recovery. Sprague-Dawley rat pups were placed in a hyperoxia chamber (inspired O(2) fraction 0.9) for postnatal days 2-14. Pups were randomized to daily intramuscular injections of rhVEGF(165) (20 microg/kg) or saline (controls). On postnatal day 14, rats were placed in room air for a 7-day recovery period. At postnatal days 3, 14, and 21, rats were killed for studies, which included body weight and wet-to-dry lung weight ratio, morphometric analysis [including radial alveolar counts (RAC), mean linear intercepts (MLI), and vessel density], and lung endothelial NO synthase (eNOS) protein content by Western blot analysis. Compared with room air controls, hyperoxia increased pulmonary edema by histology and wet-to-dry lung weight ratios at postnatal day 3, which resolved by day 14. Although treatment with rhVEGF did not increase edema in control rats, rhVEGF increased wet-to-dry weight ratios in hyperoxia-exposed rats at postnatal days 3 and 14 (P < 0.01). Compared with room air controls, hyperoxia decreased RAC and increased MLI at postnatal days 14 and 21. Treatment with VEGF resulted in increased RAC by 181% and decreased MLI by 55% on postnatal day 14 in the hyperoxia group (P < 0.01). On postnatal day 21, RAC was increased by 176% and MLI was decreased by 58% in the hyperoxia group treated with VEGF. rhVEGF treatment during hyperoxia increased eNOS protein on postnatal day 3 by threefold (P < 0.05). We conclude that rhVEGF treatment during hyperoxia-induced ALI transiently increases pulmonary edema but improves lung structure during late recovery. We speculate that VEGF has diverse roles in hyperoxia-induced neonatal lung injury, contributing to lung edema during the acute stage of ALI but promoting repair of the lung during recovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16829629     DOI: 10.1152/ajplung.00093.2006

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  52 in total

1.  Efficacy of Leukadherin-1 in the Prevention of Hyperoxia-Induced Lung Injury in Neonatal Rats.

Authors:  Jawahar Jagarapu; Jelte Kelchtermans; Min Rong; Shaoyi Chen; Dorothy Hehre; Stefanie Hummler; Mohd Hafeez Faridi; Vineet Gupta; Shu Wu
Journal:  Am J Respir Cell Mol Biol       Date:  2015-12       Impact factor: 6.914

Review 2.  Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease.

Authors:  Bernard Thébaud; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2007-02-01       Impact factor: 21.405

3.  Intrauterine growth restriction decreases pulmonary alveolar and vessel growth and causes pulmonary artery endothelial cell dysfunction in vitro in fetal sheep.

Authors:  Paul J Rozance; Gregory J Seedorf; Alicia Brown; Gates Roe; Meghan C O'Meara; Jason Gien; Jen-Ruey Tang; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-08-26       Impact factor: 5.464

4.  Recombinant CCN1 prevents hyperoxia-induced lung injury in neonatal rats.

Authors:  Ruben Vaidya; Ronald Zambrano; Julia K Hummler; Shihua Luo; Matthew R Duncan; Karen Young; Lester F Lau; Shu Wu
Journal:  Pediatr Res       Date:  2017-08-02       Impact factor: 3.756

Review 5.  Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension.

Authors:  Bradley A Maron; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

Review 6.  The thioredoxin system in neonatal lung disease.

Authors:  Trent E Tipple
Journal:  Antioxid Redox Signal       Date:  2014-03-13       Impact factor: 8.401

7.  Bone marrow-derived angiogenic cells restore lung alveolar and vascular structure after neonatal hyperoxia in infant mice.

Authors:  Vivek Balasubramaniam; Sharon L Ryan; Gregory J Seedorf; Emily V Roth; Thatcher R Heumann; Mervin C Yoder; David A Ingram; Christopher J Hogan; Neil E Markham; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-11       Impact factor: 5.464

8.  Exploiting cellular-developmental evolution as the scientific basis for preventive medicine.

Authors:  J S Torday; V K Rehan
Journal:  Med Hypotheses       Date:  2009-01-14       Impact factor: 1.538

9.  Intrauterine pulmonary hypertension impairs angiogenesis in vitro: role of vascular endothelial growth factor nitric oxide signaling.

Authors:  Jason Gien; Gregory J Seedorf; Vivek Balasubramaniam; Neil Markham; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2007-09-06       Impact factor: 21.405

Review 10.  Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia.

Authors:  Vineet Bhandari
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.